← ANALYST RATINGS · TIPRANKS

Niagen Bioscience (NAGE): analyst forecast and price target

$2.49 −3.49% close 16.10.26 · market cap $200M · Consumerdefensive · Biotechnology IWM 0.01%

Price targets and ratings of

All analysts Top analysts

Analyst consensus

Moderate Buy

2 Buy0 Hold0 Sell

Ratings of 2 analysts in the last 3 months · top analysts only

12-month forecast

$10.50+321.7% upside

Based on 2 price targets given in the last 3 months, the average target is $10.50, the highest $11.00, the lowest $10.00. The average is +321.7% from the last price of $2.49.

Highest target $11.00 Average target $10.50 Lowest target $10.00

Analyst ratings 5

Analysts TipRanks AI models 6 All

Any rating Buy Hold Sell

All actions Only changes

Analyst	Firm	Price target	Rating	Upside	Action	Date	Move vs SPY
Sean McGowan★★★★★★★★★★#9856 · hits 35% · avg −0.8%	Roth MKM	$10.00	Buy	+301.6%	Reiterated	12.10.26on TipRanks 08:10	−2.2%next day −1.9%	↗
Susan Anderson★★★★★★★★★★#576 · hits 45% · avg +16.7%	Canaccord Genuity	$10.00	Buy	+301.6%	Reiterated	05.10.26on TipRanks 07:16	−4.6%next day −0.2% · 5 days −2.3%	↗
AI xAi BiotechnologyxAI Grok-4	TipRanks - xAI	$3.50 → $3.00−14.3%	Buy	+20.5%	Reiterated	02.10.26on TipRanks 12:05	—
AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale	TipRanks - DeepSeek	$3.50 → $3.00−14.3%	Hold	+20.5%	Reiterated	02.10.26on TipRanks 12:05	—
AI OpenAI BiotechnologyOpenAI 5.2	TipRanks - OpenAI	$3.50 → $3.00−14.3%	Hold	+20.5%	Reiterated	02.10.26on TipRanks 12:05	—
AI Anthropic BiotechnologyAnthropic Opus-4.6	TipRanks - Anthropic	$3.50 → $3.00−14.3%	Hold	+20.5%	Reiterated	02.10.26on TipRanks 12:05	—
AI Google BiotechnologyGemini 3.1Pro	TipRanks - Google	$3.50 → $3.00−14.3%	Buy	+20.5%	Reiterated	02.10.26on TipRanks 12:05	—
AI PerPlexity BiotechnologyPerPlexity SonarPro	TipRanks - PerPlexity	$3.50 → $3.00−14.3%	Hold	+20.5%	Downgrade	02.10.26on TipRanks 12:05	—
Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4%	H.C. Wainwright	$11.00	Buy	+341.8%	Reiterated	05.08.26on TipRanks 06:16	−14.5%next day +2.9% · 5 days +3.0%	↗
Jeffrey Cohen★★★★★★★★★★#11115 · hits 35% · avg −2.9%	Ladenburg Thalmann & Co.	$12.00 → $11.00−8.3%	Buy	+341.8%	Reiterated	21.07.26on TipRanks Jul 24 21:24	+2.7%next day −2.6% · 5 days −4.7%	↗
Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5%	Freedom Capital Markets	$9.00	Buy	+261.4%	Initiated	06.07.26on TipRanks 15:15	+1.2%next day −1.0% · 5 days −0.6%	↗
No ratings for this filter.

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering Niagen Bioscience

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Jeffrey Cohen★★★★★★★★★★Ladenburg Thalmann & Co. · #11115

Hits 35%66 of 189 Average return −2.9%

1 year Jeffrey Cohen★★★★★★★★★★Ladenburg Thalmann & Co. · #11115

Hits 35%66 of 189 Average return −2.9%

2 years Jeffrey Cohen★★★★★★★★★★Ladenburg Thalmann & Co. · #11115

Hits 35%66 of 189 Average return −2.9%

Most profitable

3 months Sean McGowan★★★★★★★★★★Roth MKM · #9856

Hits 35%83 of 236 Average return −0.8%

1 year Sean McGowan★★★★★★★★★★Roth MKM · #9856

Hits 35%83 of 236 Average return −0.8%

2 years Jeffrey Cohen★★★★★★★★★★Ladenburg Thalmann & Co. · #11115

Hits 35%66 of 189 Average return −2.9%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.20 at a price of $2.92 (+249.3%); now: $10.50 at $2.49 (+321.7%).

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

Strong BuyBuyHoldSell

Rating	05.26	06.26	07.26	08.26	09.26	10.26
Strong Buy	5	3	5	6	8	7
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0

Earnings and sales forecast

Next report: 04.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.01 (from $-0.03 to $0.06). Last quarter: $0.01.

Sales

Next quarter’s sales estimate — $34M (from $27M to $38M). Last quarter: $30M.

Best top-analyst consensus in the sector · Consumerdefensive

JBSJBS

MAMAMama's Creations

WMTWalmart

BGBunge Global

TPBTurning Point Brands

About Niagen Bioscience

CEO: Robert N. Fried
Employees: 117
10900 Wilshire Blvd, Suite 600, Los Angeles, CA, 90024, US
www.niagenbioscience.com

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Data from the stock’s TipRanks forecast page, read 110 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗